Risk Factors for Hepatocellular Carcinoma in India

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue , 2014, Pages S34-S42

  Kar, Premashis ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Aflatoxin; HCC; Risk factor

Indexed keywords

AFLATOXIN; AFLATOXIN B;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HUMAN; INDIA; INDIAN; INFECTION PREVENTION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84954196869     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.02.155     Document Type: Review

References (94)

1. Di Bisceglie A.M., Rustgi V.K., Hoofnagle J.H., Dusheiko G.M., Lotze M.T. Hepatocellular carcinoma. Ann Intern Med 1988, 108:390-401.
2. Chisari F.V., Klopchin K., Moriyama T., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59:1145-1156.
3. Idilman R., De Maria N., Colantoni A., Van Thiel D.H. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat 1998, 5(5):285-299.
4. Feitelson M. Hepatitis-B x-antigen in the pathogenesis of hepatocellular-carcinoma (review). Oncol Rep 1995 Mar, 2(2):193-202.
5. Paterlini P., Driss F., Pisi E., et al. Persistence of hepatitis B and C viral genomes in primary liver cancers from HBsAg negative patients: a study of a low endemic area. Hepatology 1993, 17:20-29.
6. Bréchot C., Minami M., De Mitri S., Paterlini P. Hepatitis B and C viruses in hepatitis B surface antigen negative hepatocellular carcinoma patients. Princess Takamatsu Symp 1995, 25:199-209.
7. Takano S., Yokosuka O., Imazeki F., Tagawa M., Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995 Mar, 21(3):650-655.
8. Tsukuma H., Hiyama T., Tanaka S., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993 Jun 24, 328(25):1797-1801.
9. Nalpas B., Martin S., Fontaine H., et al. Impact of medical recommendations on alcohol consumption in HCV positive patients. J Hepatol 2001, 35(2):312-313.
10. Guptan R.C., Thakur V., Sarin S.K., Banerjee K., Khandekar P. Frequency and clinical profile of precore and surface hepatitis B mutants in Asian-Indian patients with chronic liver disease. Am J Gastroenterol 1996 Jul, 91(7):1312-1317.
11. World Gastroenterology Organisation Global Guideline. Hepatocellular Carcinoma (HCC): A Global Perspective November 2009.
12. Okuda K., Fujimoto I., Hanai A., Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987, 47:4967-4972.
13. Okuda K. New trends in hepatocellular carcinoma. Int J Clin Lab Res 1993, 23(4):173-178.
14. Nellithady G.S., Anila K., Kumar K.K., Kaveri H. Lack of association of chronic liver disease in patients with oral Lichen planus. J Carcinog Mutagene 2010, 1:113.
15. Cariani E., Lasserre C., Seurin D., et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988 Dec 1, 48(23):6844-6849.
16. Kinami Y., Takashima S., Miyazaki I. Hepatic resection for hepatocellular carcinoma associated with liver cirrhosis. World J Surg 1986 Apr, 10(2):294-301.
17. Liu Z.M., Li L.Q., Peng, et al. Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and highrisk for hepatocellular carcinoma. Cancer Lett 2008, 263(2):212-222.
18. Oka H., Kurioka N., Kim K., et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990 Oct, 12(4 Pt 1):680-687.
19. Colombo M., de Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991 Sep 5, 325(10):675-680.
20. Yu M.W., Hsu F.C., Sheen I.S., et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997, 145(11):1039-1047.
21. Li H., Wang G., Wang A., Tong W., Zhang Y. Alcohol consumption and risk of type 2 diabetes in Mongolian population, inner Mongolia, China. J Diabetes Metab 2011, 2:116.
22. Austin H., Deizell E., Grufferman, et al. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking and alcohol consumption. Cancer Res 1986, 46:962-966.
23. Ozturk M., Bressae B., Puisieux, et al. P53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338:113-122.
24. Lunn R.M., Zhang Y.-J., Wang, et al. P53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997, 57:3471-3477.
25. Chen S.Y., Chen C.J., Chou S.R., et al. Association of aflatoxin B(1)-albumin adduct levels with hepatitis B surface antigen status among adolescents in Taiwan. Cancer Epidemiol Biomarkers Prev 2001, 10(11):1223-1226.
26. Sarin S.K.T.V., Guptan R.C., Saigal S., Malhotra V., Thyagarajan S.P., Das B.C. Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. J Gastroenterol Hepatol 2001, 16:666-673.
27. Singh S., Sarin S.K. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004, 119145-119148.
28. Edman J.C., Gray P., Valenzuela P., et al. Integration of hepatitis B virus sequences and their expression in human hepatoma cell. Nature 1980, 286:535-538.
29. Ishikawa T., Ishibashi J., Yamashita K., et al. Non-thermal effects of far-infrared Ray (FIR) on human hepatocellular carcinoma cells HepG2 and their tumors. J Cancer Sci Ther 2009, 1:78-82.
30. Kaneko M., Suzuki H., Watanabe H., Oda E., Aizawa Y. Metabolic syndrome is a poor predictor of incident diabetes compared with hemoglobin A1c (Hba1c) in a general Japanese population. J Diabetes Metab S 2011, 2.
31. Ramachandra S. Do we need yet another Insulin?. J Diabet Metabol 2011, 2:0e4.
32. Takasaki S. Mitochondrial haplogroups associated with Japanese centenarians, Alzheimer's patients, Parkinson's patients, type 2 diabetes patients, healthy non-obese young males, and obese young males. J Proteomics Bioinform 2011, 4:106-112.
33. Kablan A., Saunders R.A., Szkudlarek-Mikho M., et al. Prieurianin causes weight loss in diet-induced obese mice and inhibits adipogenesis in cultured preadipocytes. J Diabetes Metab 2010, 1:101.
34. Shanker J.H., Mahmood S.E., Joshi M.C., Shaifali I. Obesity indices amongst diabetics in an urban population of western Nepal. J Diabetes Metab 2011, 2:134.
35. Amarapurkar D.N., Amarapurkar A.D. Non-alcoholic steatohepatitis: clinicopathological profile. J Assoc Physic India 2000, 48:311-313.
36. Kumar M., Kumar R., Hissar S.S., et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case- control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol Jul 2007, 22(7):1104-1111. Epub 2007 Jun 7.
37. Asim M., Sarma M.P., Thayumanavan L., Kar P. Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population. Clin Biochem 2011 Oct, 44(14-15):1235-1240.
38. Asim M., Malik A., Sarma M.P., et al. Hepatitis B virus BCP, Precore/core, X gene mutations/genotypes and the risk of hepatocellular carcinoma in India. J Med Virol July 2010, 82(7):1115-1125.
39. Pujol F.H., Navas M.C., Hainaut P., Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009 Dec 1, 286(1):80-88.
40. Vivekanandan P., Torbenson M., Ramakrishna B. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes. J Gastrointest cancer 2011, 42(1):20-25.
41. Sarma Manash Pratim, Asim Mohammad, Medhi Subhash, Bharathi Thayumanavan, Diwan Richa, Kar Premashis Viral genotypes and associated risk factors of hepatocellular carcinoma in India. Cancer Biol Med 2012, 9:172-181.
42. Paul Shashi Bala, Sreenivas Vishnubhatla, Gulati Manpreet Singh, et al. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India. Indian J Gastroenterol 2007, 26. (Nov-Dec).
43. Tripathy Anuradha S., Shankarkumar U., Chadha Mandeep S., Ghosh Kanjashkya, Arankalle Vidya A. Association of HLA alleles with hepatitis C infection in Maharashtra, western India. Indian J Med Res November 2009, 130:550-555.
44. Anitha S. Assessment of Aflatoxin Exposure Among Indian Population 2011, PhD thesis, Nizam's Institute of Medical Sciences. http://oar.icrisat.org/id/eprint/5268.
45. Dhir V., Mohandas K.M. Epidemiology of digestive cancer in India-III: liver. Indian J Gastroenterol 1998, 17:100-103.
46. Chen C.J., Zhang Y.J., Lu S.N., Santell R.M. Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. Hepatology 1992, 16:1150-1155.
47. Chen C., Huang M., Yang I., et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006, 40:745-752.
48. IARC (International Agency for Research on Cancer) Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 2002, 82:171-300.
49. Wang J.S., Huang T., Su J., et al. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2001, 10:143-146.
50. Yoon K.H., Lee J.H., Kim J.W., et al. Epidemic obesity and type II diabetes in Asia. Lancet 2006, 368:1681-1688.
51. Amarapurkar D.N., Patel N.D. Increased prevalence of type II diabetes mellitus in hepatitis C virus infection in Western India. Trop Gastroenterol 2008, 29:148-152. troenterol 2006;40:58-76.
52. Definition and Diagnosis of Diabetes Mellitus 2008, WHO.
53. Amarapurkar D.N., Das H.S. Chronic liver disease in diabetes mellitus. Trop Gastroenterol 2002, 23:3-5.
54. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
55. Regimbeau J.M., Colombat M., Mognol P., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004, 10:S69-S73.
56. Baig N., Herrine S., Rubin R. Liver disease and diabetes mellitus. Clin Lab Med 2001, 21:193-207.
57. Petrides A.S. Liver disease and diabetes Mellitus. Diabetes Rev 1994, 2:2-18.
58. Holstein A., Hinze S., Thieben E. Clinical implication of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002, 17:677-684.
59. Vanni E., Abate M.L., Gentilcore, et al. Sites of insulin resistance in non obese, non diabetic patients with chronic hepatitis C. Hepatology 2009, 50:697-706.
60. Lawson D.H., Gray J.M., McKillop C., Clarke J., Lee F.D., Patrick R.S. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986, 61:945-955.
61. Fujino Y., Mizoue T., Tokui N., Yoshimura T. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 2001, 17:374-379.
62. Li F.Q., Yoshizawa T., Kawamura O., Luo X.Y., Li Y.W. Aflatoxins and fumonisins in corn from the high-incidence area for human hepatocellular carcinoma in Guangxi, China. J Agric Food Chem 2001, 49(8):4122-4126.
63. Lai M.S., Hsieh M.S., Chiu Y.H., Chen T.H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006, 43:1295-1302.
64. Huo T.I., Wu J.C., Lui W.Y., et al. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol 2003, 15:1203-1208.
65. Poon R.T., Fan S.T., Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma?. Am J Gastroenterol 2002, 97:1480-1488.
66. Marrero J.A., Fontana R.J., Fu S., Conjeevaram H.S., Su G.L., Lok A.S. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005, 42:218-224.
67. Murugavel K.G., Naranatt P.P., Shankar E.M., et al. Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test. J Med Microbiol 2007, 56:1455-1459.
68. Groopman J.D., Kensler T.W., Wild C.P. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev Public Health 2008, 29:187-203.
69. Van Rensburg S.J., Cook-Mozaffari P., Van Schalkwyk D.J., Van Der Watt J.J., Vincent T.J., Purchase I.F. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 1985, 51:713-726.
70. Lin J.K., Mille J.A., Miller E.C. 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy-aflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or ribosomal RNA adducts formed in hepatic microsomemediated reactions in rat liver in vivo. Cancer Res 1977, 37:4430-4438.
71. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
72. Caldwell S.H., Oliveira C.P.M.S., de Lima V.M.R., Park S.H. NASH, Cryptogenic Cirrhosis and Hepatocellular Carcinoma 2007, Chapter in International update on Hepatology, Permanyer Publication. R. Bataller (Ed.).
73. Laurent-Puig P., Legoix P., Bluteau O., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
74. McMahon G., Davis E.F., Huber L.J., Kim Y., Wogan G.N. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc Natl Acad Sci U S A 1990, 87:1104-1108.
75. Kirk G.D., Lesi O.A., Mendy M., et al. 249(ser) P53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005, 24(38):5858-5867.
76. Kuang S.-Y., Lekawanvijit S., Maneekarn N., et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005, 14(2):380-384.
77. Wild C.P., Jiang Y.Z., Sabbioni G., Chapot B., Montesano R. Evaluation of methods for quantification of aflatoxin-albumin and their application to human exposure assessment. Cancer Res 1990, 50:245-251.
78. Behal R., Jain R., Behal K.K., Bhagoliwal A., Aggarwal N., Dhole T.N. Seroprevalence and risk factors for hepatitis B virus infection among general population in Northern India. Arq Gastroenterol 2008, 45(2):137-140.
79. Liu Yan, Wu Felicia Global Burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010 June, 118(6):818-824.
80. Henry S.H., Bosch F.X., Troxell T.C., Bolger P.M. Policy forum: public health. Reducing liver cancer-global control of aflatoxin. Science 1999, 286(5449):2453-2454.
81. International Programme on Chemical Safety and WHO International Programme on Chemical Safety. Safety Evaluation of Certain Food Additives and Contaminants. WHO Food Additives Series 40 1998, IPCS/WHO 1998, Available:. http://www.inchem.org/documents/jecfa/jecmono/v040je01.htm.
82. Strosnider H., Azziz-Baumgartner E., Banziger M., et al. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect 2006, 114:1898-1903.
83. Wild C.P., Gong Y.Y. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010, 31:71-82.
84. Busby W.F., Wogan G.N. Aflatoxins. Chemical Carcinogens 1984, vol. 2:945-1136. American Chemical Society, Washington, DC. 2nd ed.
85. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991, 350:427-428.
86. Ross R.K., Yuan J.M., Yu M.C., et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992, 339:943-946.
87. Williams J.H., Phillips T.D., Jolly P.E., Stiles J.K., Jolly C.M., Aggarwal D. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004, 80:1106-1122.
88. Peers F., Bosch X., Kaldor J., Linsell A., Pluijmen M. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 1987 May 15, 39(5):545-553.
89. Yeh F.S., Yu M.C., Mo C.C., Luo S., Tong M.J., Henderson B.E. Hepatitis B virus, aflatoxins and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 1989, 49:506-2509.
90. IARC Aflatoxins. IARC Monogr Eval Carcinog Risks Hum 1993, 56:245-395.
91. Lam K.C., Yu M.C., Leung J.W.C., Henderson B.E. Molecular viral oncology of hepatocellular carcinoma. Oncogene 1982, 22:5093-5107.
92. Lu S.N., Lin T.M., Chen C.J., et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988, 62:2051-2055.
93. Campbell T.C., Chen J., Liu C., Li J., Parpia B. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc Natl Acad Sci U S A 1990, 87:1104-1108.
94. Perz Joseph F., Armstrong Gregory L., Farrington Leigh A., Hutin Yvan J.F., Bell Beth P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.